Oncol Case Rep J | Volume 6, Issue 2 | Case Report | Open Access

Rucaparib in Platinum-Resistant High-Grade Serous Ovarian Cancer: Case Report

Sharma M^1* and Bharat S²

¹Department of Oncology, Institution-Action Cancer Hospital, India
²Institution-Zydus Lifesciences LTD, Gujarat, India

^*Correspondance to: Manish Sharma 

Fulltext PDF

Abstract

High-Grade Serous Ovarian Carcinoma (HGSOC) is the most frequent type of ovarian cancer and has a poor outcome. A 57-year-old menopausal patient with hypertension, type 2 diabetes mellitus, and hypothyroidism presented with a complaint of pain in the abdomen for the duration of 2 to 3 weeks along with abdominal distention, alternating constipation and diarrhea, and nausea with a history of cholecystectomy and breast cancer. The patient's condition was further complicated by dilated cardiomyopathy of the left ventricle that led to congestive heart failure, most probably due to chemotherapy given for breast cancer. Histopathological examination confirmed the diagnosis of high-grade serous ovarian carcinoma, and the patient received neoadjuvant chemotherapy, interval debulking surgery, and adjuvant chemotherapy. Positron Emission Tomography-Computed Tomography (PET/CT) scan showed no evidence of disease post-chemotherapy. Genetic testing revealed that the patient was mutation-positive in germline Breast Cancer Gene 2 (BRCA2). The patient's CA-125 level started to rise after three months of the last platinum-based chemotherapy (Platinum resistant); hence, Rucaparib 600 mg BID was started, and the patient remained progression-free for almost a year.

Keywords:

Ovarian cancer; Platinum resistant HGSOC; Rucaparib; CA-125

Citation:

Sharma M, Bharat S. Rucaparib in Platinum-Resistant High-Grade Serous Ovarian Cancer: Case Report. Oncol Case Report J. 2023; 6(2): 1058..